LillyDirect
Eli Lilly’s direct-to-consumer channel selling Zepbound single-dose vials to cash payers — $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5–15 mg — the price floor for approved tirzepatide and the benchmark every compounded figure on this site is measured against.
Released · Last reviewed · how we verify
Seen against the November 20, 2026 re-read: compounded tirzepatide runs from $85.58 to $399 and semaglutide from $75.58 to $299 per billing cycle, all-in, among programs that print a comparable price, so terms like this one decide whether the advertised number matches the bill. Every definition in this glossary links back to the places in the database and the methodology where the concept does its work.
The concrete stakes today: the vial ladder ($299/$399/$449) is the ceiling every compounded tirzepatide price argues against. Related figures live on the pages this term links to, and every one of them regenerates from the same dataset this definition does.
See the term in action across the price database and the methodology.